Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1

Huabing Zhang, Sadeesh K. Ramakrishnan, Daniel Triner, Brook Centofanti, Dhiman Maitra, Balázs Gyorffy, Judith S. Sebolt-Leopold, Michael K. Dame, James Varani, Dean E. Brenner, Eric R. Fearon, M. Bishr Omary, Yatrik M. Shah

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Yes-associated protein 1 (YAP1) is a transcriptional coactivator in the Hippo signaling pathway. Increased YAP1 activity promotes the growth of tumors, including that of colorectal cancer (CRC). Verteporfin, a drug that enhances phototherapy to treat neovascular macular degeneration, is an inhibitor of YAP1. We found that verteporfin inhibited tumor growth independently of its effects on YAP1 or the related protein TAZ in genetically or chemically induced mouse models of CRC, in patient-derived xenografts, and in enteroid models of CRC. Instead, verteporfin exhibited in vivo selectivity for killing tumor cells in part by impairing the global clearance of high-molecular weight oligomerized proteins, particularly p62 (a sequestrome involved in autophagy) and STAT3 (signal transducer and activator of transcription 3; a transcription factor). Verteporfin inhibited cytokine-induced STAT3 activity and cell proliferation and reduced the viability of cultured CRC cells. Although verteporfin accumulated to a greater extent in normal cells than in tumor cells in vivo, experiments with cultured cells indicated that the normal cells efficiently cleared verteporfin-induced protein oligomers through autophagic and proteasomal pathways. Culturing CRC cells under hypoxic or nutrient-deprived conditions (modeling a typical CRC microenvironment) impaired the clearance of protein oligomers and resulted in cell death, whereas culturing cells under normoxic or glucose-replete conditions protected cell viability and proliferation in the presence of verteporfin. Furthermore, verteporfin suppressed the proliferation of other cancer cell lines even in the absence of YAP1, suggesting that verteporfin may be effective against multiple types of solid cancers.

Original languageEnglish
Article numberra98
JournalScience Signaling
Volume8
Issue number397
DOIs
Publication statusPublished - Oct 6 2015

    Fingerprint

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Zhang, H., Ramakrishnan, S. K., Triner, D., Centofanti, B., Maitra, D., Gyorffy, B., Sebolt-Leopold, J. S., Dame, M. K., Varani, J., Brenner, D. E., Fearon, E. R., Omary, M. B., & Shah, Y. M. (2015). Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. Science Signaling, 8(397), [ra98]. https://doi.org/10.1126/scisignal.aac5418